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Abstract
Background: Assessment exposure and immunity to malaria is an important step in the fight against the disease.
Increased malaria infection in non-immune travellers under anti-malarial chemoprophylaxis, as well as the
implementation of malaria elimination programmes in endemic countries, raises new issues that pertain to these
processes. Notably, monitoring malaria immunity has become more difficult in individuals showing low antibody
(Ab) responses or taking medications against the Plasmodium falciparum blood stages. Commonly available
techniques in malaria seroepidemiology have limited sensitivity, both against pre-erythrocytic, as against blood
stages of the parasite. Thus, the aim of this study was to develop a sensitive tool to assess the exposure to malaria
or to bites from the vector Anopheles gambiae, despite anti-malarial prophylactic treatment.
Methods: Ab responses to 13 pre-erythrocytic P. falciparum-specific peptides derived from the proteins Lsa1, Lsa3,
Glurp, Salsa, Trap, Starp, CSP and Pf11.1, and to 2 peptides specific for the Anopheles gambiae saliva protein gSG6
were tested. In this study, 253 individuals from three Senegalese areas with different transmission intensities and
124 European travellers exposed to malaria during a short period of time were included.
Results: The multiplex assay was optimized for most but not all of the antigens. It was rapid, reproducible and
required a small volume of serum. Proportions of Ab-positive individuals, Ab levels and the mean number of
antigens (Ags) recognized by each individual increased significantly with increases in the level of malaria exposure.
Conclusion: The multiplex assay developed here provides a useful tool to evaluate immune responses to multiple
Ags in large populations, even when only small amounts of serum are available, or Ab titres are low, as in case of
travellers. Finally, the relationship of Ab responses with malaria endemicity levels provides a way to monitor
exposure in differentially exposed autochthonous individuals from various endemicity areas, as well as in travellers
who are not immune, thus indirectly assessing the parasite transmission and malaria risk in the new eradication
era.
Background
Malaria is a major threat in tropical and sub-tropical
regions, with nearly 50% of the world population
exposed to different degrees, and an estimated 250 mil-
lion people suffer annually from the disease [1]. Despite
the adoption of effective interventions like artemisinin-
based combination therapies, malaria is still a worldwide
threat mainly due to the increasing prevalence of drug-
resistant strains, the increasing risk of transmission in
countries where malaria control has been reduced, and
increased travel and migration [2]. Thus, malaria
remains a major public health problem in the 109 ende-
mic countries [3], as well as in other regions like Eur-
ope, where malaria due to travel is responsible for ca.
10,000 reported cases each year [4].
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with the efficacy of anti-vectorial strategies and anti-
malarial control measures taken by travellers, are key
factors in disease control and management, though they
are often neglected issues in infectious diseases related
to poverty, as is malaria [5]. Some indicators that help
in monitoring these factors are the incidence of clinical
malaria cases and the estimation of the exposure to vec-
tor bites. However, such methods for monitoring
malaria impact can be time-consuming, subjective and
impractical. On the other hand, serological tools can be
employed for this purpose with higher consistency and
efficacy and less cost and time [6]. Indeed, seroconver-
sion rates for malarial blood stages and pre-erythrocytic
Ags correlate closely with levels of exposure to P. falci-
parum [7]. Thus, the Ab immune response against Plas-
modium Ags can be used as one means to evaluate the
exposure to malaria in travellers, even when they take
anti-malarial chemoprophylaxis [8]. Furthermore, eva-
luation of the human response to arthropod salivary
antigens could be an epidemiological indicator of expo-
sure to vector bites, as described for the P. falciparum
vector A. gambiae [9].
Standard seroepidemiological approaches include
indirect immunofluorescence (IF) and ELISA tests,
which are labourious and have disadvantages, such as
the need for large amounts of serum and the limited
number of Ags that can be included in the test at one
time [10]. Currently, multiplex bead assays, such as
Luminex technology [11], are preferred for high-
throughput screening [12] because they are cost- and
time-effective and minimize the sample volume require-
ments [13]. Moreover, they have been described to have
similar or improved sensitivity relative to ELISA assays
[13,14], and have proved useful as a tool for the detec-
tion of serum Abs directed against infectious pathogens
[10,15,16].
The objectives of the present study were to set up a
multi-Ag assay based on multiplex technology in order
to analyse Ab responses against 13 P. falciparum pre-
erythrocytic peptides and two A. gambiae salivary pep-
tides and to examine if individuals exposed to different
levels of malaria endemicity could be differentiated.
Most of the P. falciparum Ags included in the present
study have already been considered as malaria vaccine
candidates [17]. The pre-erythrocytic Ag circumsporo-
zoite protein (CSP) is only actively expressed during the
sporozoite stage and is generally used as a reference for
the serological estimation of P. falciparum exposure
[18-20]. Thrombospondin-related anonymous protein
(Trap) [21] Ag is expressed on the surface of the sporo-
zoite and is also reportedly associated with repeated
malaria exposure [22]. Liver stage antigen-1 (LSA-1)
[23] is expressed during the hepatic stage of P.
falciparum infection. Ab responses against LSA-1
derived peptides have been previously shown to corre-
late with the cumulative exposure to malaria transmis-
sion [24]. Liver stage antigen 3 (LSA-3) [25], sporozoite
threonine- and asparagine-rich protein (Starp) [23] and
sporozoite- and liver-stage antigen (Salsa) are expressed
at both the sporozoite and hepatic stages [26] and have
been reported as antigenic [26,27]. SR11.1 Ag corre-
sponds to a unique subregion of the megaprotein Pf
11.1 (Brahimi K., et al. unpublished data; Perlaza B.L., et
al. unpublished data), and it is expressed at sporozoite
and liver stages. Glutamate-rich protein (Glurp) Ag is
expressed at each stage of parasite life in the human
host and has been shown to be antigenic [28,29].
Studies among people living in areas endemic to
malaria [30] and among travellers transiently exposed
have shown that mosquito saliva is immunogenic for A.
gambiae-specific Ags [9]. In particular, the Ab response
against gSG6 (A. gambiae’s salivary gland 6) has been
described as useful for the evaluation of the intensity of
human-Anopheles contact [31].
Methods
Sera samples
The study was conducted on three different populations:
non-exposed, transiently exposed and regularly exposed
to A. gambiae bites and P. falciparum.T w e n t y - o n e
serum samples from French adults, who have never
been in countries endemic to malaria and A. gambiae,
were used as unexposed negative controls. The transi-
ently exposed group consisted of sera from 124 French
soldiers who lived in Ivory Coast between March and
June 2004 [32]. The exposed group consisted of 253
people living in the Senegalese villages of Dielmo (13°
45’N, 16°25’W; 82 individuals, 45 of whom were adults
sampled in March 1995), Ndiop (13°14’N, 16°23’W; 86
individuals, 40 of whom were adults sampled between
March and June 1995) and Diama (16°13’ N, 16°23’W;
85 individuals, 38 of whom were adults). These popula-
tions were exposed to high (Dielmo, about 200 infective
bites/person/year) [33], moderate (Ndiop, about 20
infective bites/person/year) [34] and low (Diama, about
2 infective bites/person/year) [35-37] malaria levels, with
A. gambiae as one of the main vectors.
For the calculation of the seropositivity threshold, the
means and standard deviations (SDs) of Ab intensity of
the negative control group for all Ags were estimated.
The lower limit of positivity for each Ab was taken as
m e a n+3 . 0 9S Do ft h en e g a t i v ec o n t r o lg r o u pv a l u e s .
Under the hypothesis of a Normal distribution, values
above this limit are expected in less than 1/1000 nega-
tive individuals.
The protocol was approved by the ethical committee
of Marseille (France) and by the Senegal National Ethics
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each participant was obtained at the beginning of the
study, after a thorough explanation of its purpose.
Peptides
As peptides with molecular weights smaller than 3000 g/
mol proved to couple poorly to beads (unpublished
data), P. falciparum peptide Ags (Table 1) were synthe-
sized with an added N-terminal cysteine residue and
covalently coupled with the BSA (bovine serum albu-
min, Sigma-Aldrich, St. Louis, USA) by Genepep (Ales,
France), and were stored in aliquots at -20°C. Purity of
these Ags was estimated at or above 83% by HPLC and
mass spectrometry.
The gSG6 peptide was designed using bioinformatics
to maximize its Anopheles specificity and antigenicity, it
was then synthesized and purified (>80%) by Genosys
(Sigma-Genosys, Cambridge, UK) and then BSA-conju-
gated (N-terminal) [31].
Covalent coupling of Ags to beads
Carboxylated Luminex beads with different fluores-
cences (Biorad Inc, CA, USA) were covalently coupled
with BSA only or 15 peptide-BSA complexes using a
modification of the protocol from Luminex Corporation
(Austin, TX, USA) as follows. Beads (5 × 10
6 per assay
condition) were transferred into 1.5 ml tubes, vortexed,
sonicated (Bandelin, Berlin, Germany) and then precipi-
tated by centrifugation at 8,000 g for 2 min. Beads were
washed with 400 μl of distilled water and pellets were
resuspended in 80 μl of activation buffer (0.1 M
NaH2PO4, pH 6.2). Beads were then activated using 10
μl of 1-ethyl-3-[3dimethylaminopropyl] carbodiimide
hydrochloride (EDC, Pierce Biotechnology, Rockford,
USA) and N-hydroxysulfosuccinimide (Sulfo-NHS, 50
mg/mL, Pierce Biotechnology), vortexed and incubated
at room temperature for 20 min in the dark (IKA, Stau-
fen, Germany). Activated beads were washed twice with
400 μl of coupling buffer (50 mM of 2-[N-morpholino]
ethanesulfonic acid (MES) monohydrate pH 5, Sigma-
Aldrich) and resuspended in 400 μlo fc o u p l i n gb u f f e r
prior to peptide addition. For optimization purposes,
three different concentrations of peptides (0.075, 0.3 and
1.2 nmol) were added to the beads. Beads and peptides
were vortexed, sonicated and then incubated for 2.5 h in
the dark, with shaking at room temperature. Coupled
beads were blocked for 30 min with shaking in the dark
using 500 μl of PBS-TBN (5% BSA, 0.15% Tween-20
and 0.05% sodium azide, pH 7.4, Sigma-Aldrich) buffer.
Coupled beads were washed with 1 ml of PBS-TBN buf-
fer, resuspended in 200 μl of the same buffer and stored
at 4°C in the dark. Four aliquots of 5 × 10
6 beads were
prepared for each peptide and mixed for homogenous
coupling.
Bead-based assay
Ag-coated beads were thoroughly resuspended by vor-
texing and sonication, and were diluted in equal
volumes of PBS and MFIA (Multiplexed Fluorescence
ImmunoAssay) diluents (Charles River Laboratories Inc,
M A ,U S A )a taf i n a lc o n c e n t r a t i o no f8 0b e a d s / μlp e r
peptide. The 1.2-μm filter-bottom 96-well microtitre
plates (MSBVS 1210, Millipore, MA, USA) were pre-
wetted with washing buffer (0.15% Tween 20, and 5%
BSA in PBS pH 7.4) using a vacuum manifold (Milli-
pore). Equal volumes of beads and sera (diluted from
1:50 to 1:3200 in equal volumes of PBS and MFIA dilu-
ents) were added to the wells. Plates were incubated at
room temperature in the dark for 1 h with shaking at
500 rpm. After incubation, plates were washed eight
Table 1 Sequences of peptides used in the study
Peptide Sequence (N-terminal to C-terminal) g/mol Spectral address Reference
Lsa1-41 LAKEKLQEQQSDLEQERLAKEKLQEQQSDLEQERLAKEKEKLQC 5338,84 10 [23]
Lsa1J ERRAKEKLQEQQSDLEQRKADTKKC 3087,36 15 [23]
Lsa3NR2 VLEESQVNDDIFNSLVKSVQQEQQHNVC 3271,46 20 [25]
Lsa3RE VESVAPSVEESVAPSVEESVAENVEESVC 3032,12 25 [25]
Glurp EDKNEKGQHEIVEVEEILC 2282,39 30 [28]
GlurpP3 EPLEPFPTQIHKDYKC 1986,19 40 [29]
Salsa1 SAEKKDEKEASEQGEESHKKENSQESAC 3164,15 45 [26]
Salsa2 NGKDDVKEEKKTNEKKDDGKTDKVQEKVLEKSPKC 4060,39 50 [26]
Trap1 DRYIPYSPDRYIPYSPDRYIPYSPC 3138,44 55 [21,22]
Trap2 CHPSDGKCNCHPSDGKCNC 2046,2 60 [21,22]
StarpR STDNNNTKTISTDNNNTKTIC 2340,34 65 [27]
CSP NANPNANPNANPNANPNVDPNVDPC 2598,62 70 [19]
SR11.1 EEVVEELIEEVIPEELVLC 2254,46 75 [8]
Saliv1 EKVWVDRDNVYCGHLDCTRVATFC 2871,16 80 [46]
Saliv2 ATFKGERFCTLCDTRHFCECKETREPLC 3365,79 85 [46]
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secondary Ab (R-phycoerythrin F(ab’)2 fragment of goat
anti-human IgG, Interchim, Montluçon, France) diluted
1:500 (1 μg/ml), was added to each well. After 30 min
of incubation in the dark at room temperature with
shaking, plates were washed as described previously.
Beads were resuspended in 100 μl of a solution of 5%
BSA-PBS, pH 7.4 and finally analysed on Luminex sys-
tem. The system was set to read a minimum of 100
beads per spectral address, and results were expressed
as the median fluorescent intensity (MFI).
ELISA assay
A random sub-sample of 30 sera representative of those
used for the bead-based assays (i.e. from the four groups
: 8 travellers, 8 adults from Diama, 5 adults from Ndiop
and 9 adults from Dielmo) were also tested against the
same antigens by conventional ELISA using a method
previously described [8] that has been slightly modified,
i.e. using peptide-BSA complexes that were linked to the
beads and BSA-coated wells as control wells, i.e. without
peptide.
Statistical analysis
Statistical analyses were performed with the R software
package version 2.8 [38]. Proportions of Ab-positive
individuals, Ab levels and number of Ags recognized by
each person were analysed using the chi-squared test,
Fisher’s exact test, Kruskal-Wallis test and Spearman’s
rank correlation test, where appropriate. Differences
were considered statistically significant when p-values
were less than 0.05.
Results
Optimal serum dilution and Ag concentration
To determine the optimal Ag amount for bead coating,
three concentrations (0.075, 0.3 and 1.2 nmol) of syn-
thetic peptides were coupled to 5 × 10
6 beads. BSA-
coated beads were included as background control.
Coated beads were then incubated with the serum from
an exposed adult from Dielmo village (Figure 1). To
determine the optimal serum dilution for the analysis,
seven dilutions (from 1:50 to 1:3200) of the serum from
the exposed individual from Dielmo village were tested
in parallel (Figure 1) together with the serum from an
unexposed adult (white bars Figure 2a for 1:100
dilution).
As shown by the distribution of Ab MFI in figure 1,
all peptide concentrations were detected by the tested
serum. For the majority of peptides, the signal saturated
when 0.3 nmol of Ag was used. The lowest (0.075 nmol)
and the highest (1.2 nmol) Ag concentrations did not
yielded optimal results, the latter probably due to Ab
competition. Background values (MFI values using BSA-
coated beads) were low, compared to MFI values
obtained with other peptides, reaching a maximum of
600.
With regard to serum dilutions, the highest MFI
values were observed with the lowest 1:50 dilution (Fig-
ure 1). Nevertheless a working dilution of 1:100 was
preferred as being less sera consuming, and because as
shown in Figure 2a, 1:100 sera dilutions led to a clear
separation of MFI between the exposed (black bars, for
multiplex assay) and non exposed (white bars) indivi-
duals. MFI values obtained with the serum from the
exposed individual from Dielmo village ranged from
2130 (Trap1) to 28236 (Glurp), whereas with the serum
from the unexposed individual reached a maximum of
719 (Trap2). As expected, the background (MFI values
with BSA-coated beads) was equivalent for both sera.
Comparison between monoplex and multiplex assays
The Ab responses detected by multiplex assay (all Ags
tested in the same assay) were compared to those
detected by monoplex assay (each Ag tested in a sepa-
rate assay). As shown in Figure 2a, the results obtained
from the exposed individual’s sera (1:100 dilution) from
Dielmo village incubated with single Ag-coated beads
(gray bars) or with equal amounts of the 15 tested Ag-
coated beads (black bars) were essentially identical. MFI
values, obtained by monoplex and multiplex assays
shown in figure 2a, were compared using a linear
regression curve, and a correlation coefficient of R
2 =
0.9896 was determined. The high level of correlation
between the two assays indicated that individual pep-
tides coupled to beads did not compete for the Abs in
the serum. Similar results were obtained regardless of
serum dilution, with correlation coefficients for all pep-
tides as follows: dilution 1:50, R
2 = 0.995; 1:200, R
2 =
0.997; 1:400, R
2 =0 . 9 9 9 ;1 : 8 0 0 ,R
2 = 0.998; 1:1600, R
2 =
0.998; and 1:3200, R
2 = 0.999.
Coating stability over time
The stability of Ag-coupled beads after 1, 2 and 3
months storage at 4°C was examined by testing against
sera from the exposed and unexposed adults; results are
shown in Figures 1 and 2a. As reported in Figure 2b,
the results were consistent for all Ags, indicating that
the storage time had no effect on coupling stability,
except for the StarpR peptide. The correlation between
the results obtained with beads stored for 1 and 3
months was high, and the correlation coefficient for all
peptides except StarpR was R
2 = 0.994. Therefore,
StarpR-coupled beads had to be used within 1 month
after preparation, whereas all other Ags-coupled beads
can be stored for longer periods before use.
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Page 4 of 12Figure 1 Determining the optimal Ag concentration to be used for bead coating and the optimal serum dilution. The figure shows MFI
values obtained from the serum of an exposed adult from Dielmo village at seven different dilutions (from 1:50 to 1:3200) with beads coated
with three concentrations (0.075, 0.3 and 1.2 nmol) of synthetic peptides. All peptides were detected by the tested serum and their signals were
much higher than the background signal against BSA-coated beads (upper left graph).
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malaria exposition level
In total, 377 individuals exposed to malaria from areas
with different endemicities were tested for all of the stu-
died Ags. Among adults, for the Ags Lsa1-41, Lsa1J,
Lsa3NR2, Glurp, Salsa2, StarpR, CSP and SR11.1, the
proportion of seropositive adults increased significantly
with the malaria endemicity (Figure 3, bars from left to
right p ≤ 0.01). For GlurpP3 and Salsa1 Ags the increase
was observed with the exception of the higher exposed
group from Dielmo (Figure 3, comparison among the
three far left bars p ≤ 0.01). For the A. gambiae Saliv1
Ag (Figure 3, bottom left), the proportion of seroposi-
tives in transiently exposed adults was undetectable,
while Abs were detected in exposed adults living in vil-
lages endemic for malaria (no significant difference
among individuals from Ndiop, Diama and Dielmo). For
the four remaining Ags (Lsa3R E ,T r a p 1 ,T r a p 2 ,S a l i v 2 ) ,
Figure 2 Comparison between exposed and unexposed adults: monoplex and multiplex assays showing coated bead-stability over
time. In the upper panel (a), the same serum from the exposed individual from Dielmo village (black bars) tested in figure 1 and serum from an
unexposed adult (white bars) were compared at a dilution of 1:100 by the multiplex assay. The assay allows a clear separation of peptide-specific
MFI between the two samples, whereas the backgrounds (MFI values with BSA-coated beads) were equivalent. The serum from the exposed
individual from Dielmo village was also tested for the same Ab responses by the monoplex assay with single peptide-coated beads (gray bars).
Results with monoplex and multiplex assays were almost identical (correlation coefficient R
2 = 0.9896). The lower panel (b) shows results
obtained using peptide-coupled beads after 1 (white bars), 2 (light gray bars) and 3 (dark gray bars) months of storage at 4°C against the 1:100
diluted serum from the exposed adult from Dielmo village and the 1:100 diluted serum from the unexposed adult (black bars, superimposed to
the corresponding time delay). MFIs were consistent for all Ags, except StarpR (the correlation coefficient comparing values using coated beads
after 1 and 3 months for each peptide, except StarpR, was R
2 = 0.9874).
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Page 6 of 12Figure 3 The proportion of seropositive individuals increases with malaria exposure level. Among the adults (124 travelers, 45 from
Dielmo, 40 from Ndiop and 38 from Diama), the proportion of seropositives for Lsa1-41 (p < 0.001), Lsa1J (p < 0.001), Lsa3NR2 (p < 0.001), Glurp
(p < 0.001), GlurpP3 (p < 0.001), Salsa1 (p < 0.001), Salsa2 (p < 0.001), StarpR (p < 0.001), CSP (p < 0.001), SR11.1 (p < 0.001) and Saliv1 (p =
0.001) peptides differed significantly between groups (Fischer’s exact test). In travellers, no Abs against Saliv1 Ag were detected; Abs were
detected in exposed adults (three far left bars). 95% confidence intervals are shown in table 2.
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low to yield any significant difference. All proportions of
seropositive adults for the 15 tested Ags are listed in
Table 2, with the respective CI 95% value.
The proportion of seropositive children (<10 years
old) and young people (from 10 to 20 years old) within
the three groups living in endemic areas was also com-
pared. The comparison showed that the proportion
increased significantly with age and according to the
level of malaria exposure for the following Ags: Lsa1-41,
Lsa1J, Lsa3NR2, Glurp, GlurpP3, Salsa1, Salsa2, StarpR,
CSP, SR11.1 and Saliv1 (p ≤ 0.001).
The Intensity of specific Ab response also increases as a
function of malaria exposure
The mean of MFI values of seropositive adults are pre-
sented in Figure 4. The results shown have been cor-
rected for the MFI for each Ag (MFIAg/MFIBSA). The
median specific Ab intensity increased significantly with
the malaria exposure level for Lsa1-41 (p < 0.02), Glurp
(p < 0.002), and CSP (p = 0.002) Ags. Moreover, a simi-
lar trend was observed for some of the remaining Ags,
as shown in Figure 4. Comparisons for Lsa3RE, Trap1,
Trap2, and Saliv2 were not significant.
Number of Ags that showed seropositivity
T h en u m b e ro fA g si nt h ed i f f e r e n tg r o u p st h a tp r o -
duced seropositive results was investigated. Figure 5
shows the distribution of the mean number of P. falci-
parum Ags for which adults within the groups were ser-
opositive. The higher the exposure level to malaria, the
higher the mean number of P. falciparum Ags that pro-
duced seropositivity. In the travellers group, the median
number of P. falciparum Ags for which individuals were
seropositive was one, whereas it was three for indivi-
duals from Diama, six for individuals from Ndiop and
seven for individuals from Dielmo. The difference
between groups was significant (p < 0.0001).
Correlation of the evaluations of Ab responses by bead-
based assays and ELISA
There were significant correlations of the evaluations of
the Ab responses obtained by bead-based assay and con-
ventional ELISA assay with the peptides Lsa1-41, Lsa1-J,
Lsa3-NR2, Glurp, Glurp P3, Salsa1, Salsa2, Trap1, Starp-
R, CSP and Saliv1 (Spearman’s rank correlation coeffi-
cient ranging from 0.79 to 0.35, mean coef. 0.58; 0.0001
≤ p-values < 0.05; additional file 1). The correlations
were not significant for the Lsa3-RE, Trap2, SR11.1 and
Saliv2 peptides, possibly in relation with a lack of antige-
nicity of the peptites coated on beads or with the nar-
rowness of the differences in Ab responses to these
antigens between the sera used for the present analysis.
Discussion
In this study, a multiplex assay to simultaneously mea-
sure responses to 13 peptides derived from pre-erythro-
cytic P. falciparum Ags and 2 peptides derived from one
A. gambiae salivary Ag has been developed.
Though multiplex immunoassays have already proven
to be useful in serological [39-42] and malaria research
[10,43], the present multiplex assay is the first to include
15 peptides simultaneously and to combine P. falci-
parum and A. gambiae Ags.
No interference between bead sets was observed in the
present study (Figure 2a) or in work from others [10].
Table 2 Number and proportion of seropositives adults (%)
Travelers (N = 124) Diama (N = 38) Ndiop (N = 40) Dielmo (N = 45)
pos % 95%CI pos % 95%CI pos % 95%CI pos % 95%CI
LSA1-41 7 5,6% 2,3% 11,3% 19 50% 33% 67% 33 83% 67% 93% 39 87% 73% 95%
LSA1-J 4 3,2% 0,9% 8,1% 4 11% 3% 25% 15 38% 23% 54% 26 58% 42% 72%
LSA3-NR2 1 0,8% 0,0% 4,4% 3 8% 2% 21% 7 18% 7% 33% 15 33% 20% 49%
LSA3-RE 0 0,0% 0,0% 2,9% 0 0% 0% 9% 0 0% 0% 9% 3 7% 1% 18%
GLURP 5 4,0% 1,3% 9,2% 25 66% 49% 80% 39 98% 87% 100% 45 100% 92% 100%
GLURP P3 1 0,8% 0,0% 4,4% 7 18% 8% 34% 21 53% 36% 68% 15 33% 20% 49%
SALSA1 0 0,0% 0,0% 2,9% 7 18% 8% 34% 23 58% 41% 73% 24 53% 38% 68%
SALSA2 2 1,6% 0,2% 5,7% 16 42% 26% 59% 23 58% 41% 73% 43 96% 85% 99%
TRAP1 0 0,0% 0,0% 2,9% 0 0% 0% 9% 3 8% 2% 20% 2 4% 1% 15%
TRAP2 0 0,0% 0,0% 2,9% 0 0% 0% 9% 0 0% 0% 9% 1 2% 0% 12%
STARP-R 1 0,8% 0,0% 4,4% 3 8% 2% 21% 15 38% 23% 54% 36 80% 65% 90%
CSP 7 5,6% 2,3% 11,3% 10 26% 13% 43% 32 80% 64% 91% 43 96% 85% 99%
SR11.1 1 0,8% 0,0% 4,4% 9 24% 11% 40% 12 30% 17% 47% 29 64% 49% 78%
SALIV1 0 0,0% 0,0% 2,9% 3 8% 2% 21% 2 5% 1% 17% 5 11% 4% 24%
SALIV2 1 0,8% 0,0% 4,4% 0 0% 0% 9% 0 0% 0% 9% 0 0% 0% 8%
pos. : seropositve. 95%CI : 95% confidence interval.
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Page 8 of 12Figure 4 MFI response in seropositive individuals increased with exposure to malaria. The distribution of corrected MFI (median
fluorescent intensity) values (MFIAg/MFIBSA) within groups is shown for the peptides Lsa1-41, Lsa1J, Lsa3NR2, Glurp, GlurpP3, Salsa1, Salsa2,
StarpR, CSP, SR11.1 and Saliv1. The difference between groups was significant for Lsa1-41 (p = 0.02), Glurp (p = 0.0014) and CSP (p = 0.002),
Kruskal-Wallis test. The number of seropositive individuals per group is presented in table 2.
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plex results are consistent with those obtained by ELI-
SAs and that both methodologies are equally sensitive
[14,44]. The multiplex assay is a flexible technique,
allowing new targets to be included when required. The
simultaneous evaluation of multiple Abs leads to a
reduction in both the time needed for the measurement
and in its cost. The small volume of serum required is
an important criterion, as it is fitted to the screening
against several Ags of large populations of children,
from whom minimal amounts of blood can be obtained.
Therefore, multiplex assays can reliably test Abs to mul-
tiple Ags at one time in a fast and affordable manner.
The high price of the Luminex machine prevents how-
ever that it is as widespread as the ELISA machines.
Thirteen pre-erythrocytic peptides from P. falciparum
were included in the assay; such peptides are useful for
monitoring the exposure to the malaria parasite. Using
peptides in place of intact proteins in such immunologi-
cal essay could lead to a loss of sensitivity (i.e. ar e s t r i c -
tion on the number of epitopes) and may on occasion
give unexpected cross-reactivities. However, the peptides
chosen for the present study had been previously com-
pared to recombinant proteins in ELISA essays and
were shown to give consistent results. A high prevalence
of Ab response to pre-erythrocytic Ags has been found
in individuals living in malaria endemic areas [23,26,27],
and the level of exposure to P. falciparum correlates
with prevalence rates for those Ags [7]. In agreement
with previous data, the present results showed that for
some of these peptides, such as Lsa1-41, Lsa1J,
Lsa3NR2, Glurp, Salsa2, StarpR, CSP and SR11.1, the
proportion of seropositive individuals clearly increases
with malaria exposure levels (Figure 3), and higher Ab
response rates were seen with the Lsa1-41, Glurp,
Salsa2, and CSP peptides. This data suggests that such
Ags can be considered as possible biomarkers of expo-
sure, and further studies in such direction would be
valuable. Moreover, for all peptides shown in Figure 3,
the proportion was higher in exposed individuals living
in malaria endemic countries, compared to transiently
exposed travellers. This trend was similar for median
fluorescence intensities of Lsa1-41, Glurp, Salsa1, Salsa2
and CSP SR11.1 peptides (Figure 4). The very low
responses recorded towards LSA3-RE are in sharp con-
trast with the high prevalence rates and titers obtained
previously when using the same peptide in ELISA assays
([22], and unpublished observation in the same study
populations investigated here). This may reflect altera-
tions of antigenicity related to the coating to BSA or to
multiplex beads, and raise doubts about the results
obtained with that particular peptide in the multiplex
assay.
When evaluating the distribution of the mean number
of peptides against which individuals were seropositive,
the value was found related to the level of malaria ende-
micity to which they were exposed. Figure 5 shows that
such measurements can clearly stratify individuals based
on their exposure levels, with a clearly higher number of
peptides recognized by individuals exposed to high
malaria transmission.
In addition to pre-erythrocytic P. falciparum Ags, the
assay also included two peptides derived from one A.
gambiae salivary Ag. As previously shown, the evalua-
tion of immune responses to mosquito salivary Ags can
indicate exposure to vector bites. Studies have demon-
strated that children living in malaria endemic regions
develop Abs against the vector’s salivary proteins [30].
Thus, Abs against A. gambiae salivary Ags represent an
immunological marker of exposure to malaria vector
[30]. One of these Ag, the gSG6 salivary protein, was
first described in 1999 [45]. The gSG6 Ag is highly con-
served among Anopheles species. It was reported to be
potentially antigenic in travellers briefly exposed to Ano-
pheles bites and was more recently confirmed as anti-
genic in Senegalese children [31].
The two peptides derived from gSG6 protein included
in the assay (Saliv1 and Saliv2) were antigenic, but the
intensity of their IgG responses was peptide-dependent,
where Saliv1 showed the higher response [46]. In the
Figure 5 The number of P. falciparum peptides that produced
seropositive results increased with malaria exposure. The
distribution of the total number of P. falciparum peptides for which
each individual was seropositive is shown. The number of
recognized peptides increased significantly with the malaria
exposure level (p < 0.0001). The middle lines of the boxes represent
the median distribution; the upper lines indicate the upper quartiles
and the lower lines show the lower quartile. The upper and the
lower lines outside the boxes represent the upper and lower non-
outsider observations, respectively, while the dots are the outliers.
Ambrosino et al. Malaria Journal 2010, 9:317
http://www.malariajournal.com/content/9/1/317
Page 10 of 12present study, Saliv1 was the target of an Ab response
only in regularly exposed individuals (Figures 3 and 4,
and Table 2). The results of the present study indicated
that the immune response to Saliv1 peptide could be
used to differentiate individuals, based on their exposure
to Anopheles bites, short-term exposure in travellers and
long-term exposure in people living in endemic coun-
tries. Furthermore, immune responses against such pep-
tides are difficult to detect in briefly exposed travellers,
though a response was observed when the Abs were
tested directly against mosquito saliva [9].
It has been reported recently that the gSG6-P1 peptide
(corresponding to Saliv1) can be used to evaluate low-
level exposures to Anopheles bites, notably in Senegalese
children ≥2 years of age [31]. Unfortunately, in the pre-
sent study population, the number of young children
was too low to confirm these findings. Furthermore, the
low-level exposure group (travellers) was exposed to
Anopheles bites at a lower rate compared to Senegalese
children due shorter exposure times and systematic use
of anti-vectorial devices (impregnated bed nets, long-
sleeved battledresses and repellents). This factor,
together with the different assay used - multiplex at a
1:100 dilution of sera in our case and ELISA at a 1:20
dilution of sera in the study performed by Poinsignon et
al [31] - could explain why Abs against Saliv1 were not
detected in the travellers group. Further, the epitopes
used could be less representative of the native ones pre-
sent in humans and, therefore, less antigenic.
Conclusions
The multiplex technology developed in the present
study is a reliable and fast method to test immune
responses to P. falciparum and A. gambiae salivary Ags
in large populations, allowing efficient identification of
putative protective Abs. Furthermore, the association of
Ab responses to malaria exposure levels provides a way
to monitor exposure in differentially exposed indigenous
people, as well as in travellers not immune to the para-
site, allowing the assessment of P. falciparum transmis-
sion and malaria risk.
Additional material
Additional file 1: Correlation between Luminex and ELISA results
obtained with 30 sera. The Spearman correlation coefficient and the
Pearson correlation coefficient between Luminex and ELISA results have
been estimated on 30 sera.
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